TMBRQ / Trex Wind-down, Inc. - Documents déposés auprès de la SEC, rapport annuel, procuration

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events, Bankruptcy or Receivership

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 TREX WIND-DOWN, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-37411 TREX WIND-DOWN, INC. (Exact name of registrant as specified in its

As filed with the Securities and Exchange Commission on May 9, 2024

As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.

EX-99.1

Exhibit 99.1

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events, Bankruptcy or Receivership

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 TREX WIND-DOWN, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commission File N

EX-99.1

Exhibit 99.1

As filed with the Securities and Exchange Commission on May 9, 2024

As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 9, 2024

As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 9, 2024

As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 9, 2024

As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 9, 2024

As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 9, 2024

As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 9, 2024

As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 9, 2024

As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 9, 2024

As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 9, 2024

As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 9, 2024

As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 9, 2024

As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.

EX-99.1

Exhibit 99.1

EX-99.3

Exhibit 99.3

EX-99.2

Exhibit 99.2

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 TREX WIND-DOWN, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commission Fil

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 TREX WIND-DOWN, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commission Fil

EX-99.1

Exhibit 99.1

EX-99.2

Exhibit 99.2

EX-99.3

Exhibit 99.3

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2024 TREX WIND-DOWN, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commission

EX-99.1

Exhibit 99.1

EX-99.2

Exhibit 99.2

EX-99.3

Exhibit 99.3

STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION

Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION The corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware does hereby certify: FIRST: That at a meeting of the Board of Directors of Timber Pharmaceuticals, Inc. resolutions were duly adopted setting forth a proposed amendment of the Certificate of Incorpo

EX-99.1

Exhibit 99.1

EX-99.3

Exhibit 99.3

Financial Statements and Exhibits, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 TREX WIND-DOWN, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commission F

EX-99.2

Exhibit 99.2

Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Bankruptcy or Receivership, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Comm

EX-99.2

Exhibit 99.2

EX-99.3

Exhibit 99.3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 TIMBER PHARMACE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Com

EX-99.1

Exhibit 99.1

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES NYSE American LLC ("NYSE American" or the "Exchange") hereby notifies the Securities and Exchange Commission (the "Commission") of its intention to remove the Common Stock of Timber Pharmaceuticals, Inc.

IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE

Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: Chapter 11 TIMBER PHARMACEUTICALS, INC., et al.,1 Case No. 23-11878 (JKS) Debtors. (Joint Administration Requested) Re: D.I. 15 & 53 INTERIM ORDER APPROVING NOTIFICATION AND HEARING PROCEDURES FOR (I) CERTAIN TRANSFERS OF AND DECLARATIONS OF WORTHLESSNESS WITH RESPECT TO COMMON STOCK, (II) CERTAIN TRANSFERS OF C

Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American

Exhibit 99.2 Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American WARREN, NJ, November 28, 2023 – Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 TIMBER PHARMACE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Com

ASSET PURCHASE AGREEMENT LEO PHARMA A/S, and LEO SPINY MERGER SUB, INC., as Buyers TIMBER PHARMACEUTICALS, INC., TIMBER PHARMACEUTICALS, LLC, and BIOPHARMX, INC. as Sellers dated as of November 17, 2023 TABLE OF CONTENTS

Exhibit 10.1 ASSET PURCHASE AGREEMENT among LEO PHARMA A/S, and LEO SPINY MERGER SUB, INC., as Buyers and TIMBER PHARMACEUTICALS, INC., TIMBER PHARMACEUTICALS, LLC, and BIOPHARMX, INC. as Sellers dated as of November 17, 2023 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.01 Definitions 1 Section 1.02 Other Definitional and Interpretative Provisions 13 ARTICLE II PURCHASE AND SALE 13 Section

VRS / TIMBER PHARMACEUTICALS

Exhibit 10.3 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS A TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. VRS / TIMBER PHARMACEUTICALS ENGAGEMENT LETTER October 31, 2023 Timber Pharmaceuticals, Inc. 3 Mountain View Road Suite 100 Warren, New Jersey

Dear ________________:

Exhibit 10.4 [Date] [Name] [Address] Dear : This Retention Bonus Agreement the (“Agreement”) is entered into as of the date written below between [] (“you”) and Timber Pharmaceutical, Inc. (the “Company”) for the purpose of setting forth the requirements for you to receive additional compensation as consideration for your continued employment with and efforts on behalf of the Company as the Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 TIMBER PHARMACE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 TIMBER PHARMACE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Com

SENIOR SECURED SUPERPRIORITY PRIMING DEBTOR-IN-POSSESSION CREDIT AGREEMENT

Exhibit 10.2 SENIOR SECURED SUPERPRIORITY PRIMING DEBTOR-IN-POSSESSION CREDIT AGREEMENT THIS SENIOR SECURED SUPERPRIORITY PRIMING DEBTOR-IN-POSSESSION CREDIT AGREEMENT (this “Agreement”), dated as of November 17, 2023, is made by and between TIMBER PHARMACEUTICALS, INC., a Delaware corporation (“Holdings”), TIMBER PHARMACEUTICALS LLC, a Delaware limited liability company (“Timber”), BIOPHARMX, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 TIMBER PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Comm

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Comm

FIRST AMENDMENT TO SECURED BRIDGE LOAN AGREEMENT

Exhibit 10.1 FIRST AMENDMENT TO SECURED BRIDGE LOAN AGREEMENT This FIRST AMENDMENT TO SECURED BRIDGE LOAN AGREEMENT (this “Amendment”) is made and entered into as of October 27, 2023 by and between TIMBER PHARMACEUTICALS, INC., a Delaware corporation (“Timber Parent”), TIMBER PHARMACEUTICALS LLC, a Delaware limited liability company (“Timber”), BIOPHARMX, INC., a Nevada corporation (“BiopharmX” an

FIRST AMENDMENT TO SECURED BRIDGE LOAN AGREEMENT

Exhibit 10.1 FIRST AMENDMENT TO SECURED BRIDGE LOAN AGREEMENT This FIRST AMENDMENT TO SECURED BRIDGE LOAN AGREEMENT (this “Amendment”) is made and entered into as of October 27, 2023 by and between TIMBER PHARMACEUTICALS, INC., a Delaware corporation (“Timber Parent”), TIMBER PHARMACEUTICALS LLC, a Delaware limited liability company (“Timber”), BIOPHARMX, INC., a Nevada corporation (“BiopharmX” an

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 TIMBER PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Comm

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Co

Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance

Exhibit 99.1 Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance WARREN, NJ, September 18, 2023 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the NYSE American

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1

CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Timber Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation

Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Timber Pharmaceuticals, Inc.

CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Timber Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation

Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Timber Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commi

FORM OF AMENDMENT TO WARRANT TIMBER PHARMACEUTICALS, INC.

Exhibit 10.2 FORM OF AMENDMENT TO WARRANT OF TIMBER PHARMACEUTICALS, INC. THIS AMENDMENT (this “Amendment”), dated as of August 25, 2023, to that certain Warrant, dated as of [●] (the “Warrant”), representing a right to purchase from Timber Pharmaceuticals, Inc., a Delaware corporation (the “Company”), [●] shares (the “Warrant Shares”) of the common stock of the Company, par value $0.001 (the “Sha

TIMBER PHARMACEUTICALS, INC. TIMBER PHARMACEUTICALS LLC BIOPHARMX, INC. SECURED BRIDGE LOAN AGREEMENT

Exhibit 10.1 TIMBER PHARMACEUTICALS, INC. TIMBER PHARMACEUTICALS LLC BIOPHARMX, INC. SECURED BRIDGE LOAN AGREEMENT $3,000,000.00 August 30, 2023 FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, each of TIMBER PHARMACEUTICALS, INC., a Delaware corporation (“Timber Parent”), TIMBER PHARMACEUTICALS LLC, a Delaware limited liability company (“Timber”), BIOPHARMX, INC., a N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2023 TIMBER PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commi

FORM OF AMENDMENT TO WARRANT TIMBER PHARMACEUTICALS, INC.

Exhibit 10.2 FORM OF AMENDMENT TO WARRANT OF TIMBER PHARMACEUTICALS, INC. THIS AMENDMENT (this “Amendment”), dated as of August 25, 2023, to that certain Warrant, dated as of [●] (the “Warrant”), representing a right to purchase from Timber Pharmaceuticals, Inc., a Delaware corporation (the “Company”), [●] shares (the “Warrant Shares”) of the common stock of the Company, par value $0.001 (the “Sha

TIMBER PHARMACEUTICALS, INC. TIMBER PHARMACEUTICALS LLC BIOPHARMX, INC. SECURED BRIDGE LOAN AGREEMENT

Exhibit 10.1 TIMBER PHARMACEUTICALS, INC. TIMBER PHARMACEUTICALS LLC BIOPHARMX, INC. SECURED BRIDGE LOAN AGREEMENT $3,000,000.00 August 30, 2023 FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, each of TIMBER PHARMACEUTICALS, INC., a Delaware corporation (“Timber Parent”), TIMBER PHARMACEUTICALS LLC, a Delaware limited liability company (“Timber”), BIOPHARMX, INC., a N

Timber Pharmaceuticals to be Acquired by LEO Pharma ● Transaction Provides Timber Stockholders with Upfront Cash Consideration and Downstream Value through Contingent Value Rights ● Total Transaction Value of up to $36 million ● Transaction Expected

Exhibit 99.1 Timber Pharmaceuticals to be Acquired by LEO Pharma ● Transaction Provides Timber Stockholders with Upfront Cash Consideration and Downstream Value through Contingent Value Rights ● Total Transaction Value of up to $36 million ● Transaction Expected to Close in the 4th Quarter of 2023, subject to closing conditions and stockholder approval WARREN, NJ. – August 21, 2023 – Timber Pharma

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2023 TIMBER PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commi

Amendment No. 2 to Asset Acquisition Agreement, dated August 20, 2023, by and among Timber Pharmaceuticals LLC, Patagonia Pharmaceuticals LLC, Johnathan Rome and Zachary Rome.

Exhibit 10.1 AMENDMENT NO. 2 TO ASSET ACQUISITION AGREEMENT (THIS “AMENDMENT”) Reference is made to that certain Asset Acquisition Agreement, dated February 28, 2019 (the “Agreement”) by and among Timber Pharmaceuticals LLC, a Delaware limited liability company (the “Company”), Patagonia Pharmaceuticals LLC, a New Jersey limited liability company (“Patagonia”), Jonathan Rome (“J Rome”) and Zachary

Press Release, dated August 21, 2023.

Exhibit 99.1 Timber Pharmaceuticals to be Acquired by LEO Pharma ● Transaction Provides Timber Stockholders with Upfront Cash Consideration and Downstream Value through Contingent Value Rights ● Total Transaction Value of up to $36 million ● Transaction Expected to Close in the 4th Quarter of 2023, subject to closing conditions and stockholder approval WARREN, NJ. – August 21, 2023 – Timber Pharma

Amendment No. 2 to Asset Acquisition Agreement, dated August 20, 20223, by and among Timber Pharmaceuticals LLC, Patagonia Pharmaceuticals LLC, Jonathan Rome and Zachary Rome (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 001-37411) file with the Commission on August 21, 2023).

Exhibit 10.1 AMENDMENT NO. 2 TO ASSET ACQUISITION AGREEMENT (THIS “AMENDMENT”) Reference is made to that certain Asset Acquisition Agreement, dated February 28, 2019 (the “Agreement”) by and among Timber Pharmaceuticals LLC, a Delaware limited liability company (the “Company”), Patagonia Pharmaceuticals LLC, a New Jersey limited liability company (“Patagonia”), Jonathan Rome (“J Rome”) and Zachary

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001

Agreement and Plan of Merger, dated August 20, 2023, by and among Timber Pharmaceuticals, Inc., LEO US Holding, Inc., Leo Spiny Merger Sub, Inc. and LEO Pharma A/S.*

Exhibit 2.1 Table of Contents AGREEMENT AND PLAN OF MERGER among LEO US HOLDING, INC., LEO SPINY MERGER SUB, INC., TIMBER PHARMACEUTICALS, INC. and LEO PHARMA A/S, as Guarantor Dated as of August 20, 2023 Table of Contents TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01. Definitions 1 Section 1.02. Other Definitional and Interpretative Provisions 13 ARTICLE 2 THE MERGER 13 Section 2.01

Agreement and Plan of Merger, dated August 20, 2023, by and among Timber Pharmaceuticals, Inc., LEO US Holding, Inc., Leo Spiny Merger Sub, Inc. and LEO Pharma A/S.*

Exhibit 2.1 Table of Contents AGREEMENT AND PLAN OF MERGER among LEO US HOLDING, INC., LEO SPINY MERGER SUB, INC., TIMBER PHARMACEUTICALS, INC. and LEO PHARMA A/S, as Guarantor Dated as of August 20, 2023 Table of Contents TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01. Definitions 1 Section 1.02. Other Definitional and Interpretative Provisions 13 ARTICLE 2 THE MERGER 13 Section 2.01

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period

Amendment to the Timber Pharmaceuticals, Inc. 2020 Omnibus Incentive Plan, dated June 23, 2023.*

Exhibit 4.11 AMENDMENT TO TIMBER PHARMACEUTICALS, INC. 2020 OMNIBUS EQUITY INCENTIVE PLAN Dated: June 23, 2023 This Amendment amends the Timber Pharmaceuticals, Inc. 2020 Omnibus Equity Incentive Plan, as amended (as amended, the “Plan”). All capitalized terms not defined herein shall have the meanings set forth in the Plan. R E C I T A L S WHEREAS, Section 17.2 of the Plan reserves to the Board o

Filing Fee Table.*

Exhibit 107.1 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Timber Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stoc

As filed with the Securities and Exchange Commission on August 2, 2023

As filed with the Securities and Exchange Commission on August 2, 2023 Registration No.

Timber Pharmaceuticals Discloses Communication From NYSE American

Exhibit 99.1 Timber Pharmaceuticals Discloses Communication From NYSE American WARREN, NJ, July 3, 2023 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that on June 28, 2023 it received a letter (the “

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 TIMBER PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 TIMBER PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commiss

Investor Presentation

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 TIMBER PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 TIMBER PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commiss

Timber Pharmaceuticals to Present Interim Analyses from Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis - First presentation of data from Phase 3 ASCEND study will feature pharmacokinetic results that indicate minimal systemic absorption of

Exhibit 99.1 Timber Pharmaceuticals to Present Interim Analyses from Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis - First presentation of data from Phase 3 ASCEND study will feature pharmacokinetic results that indicate minimal systemic absorption of isotretinoin - - Data to be presented at the Society for Pediatric Dermatology’s Annual Meeting - WARREN, NJ, June 20, 2023 – Timber Phar

Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001 - Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis is 70% enrolled -

Exhibit 99.1 Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001 - Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis is 70% enrolled - WARREN, NJ, June 5, 2023 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 TIMBER PHARMACEUTICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2023 TIMBER PHARMACEUTICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00

Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results - Timber has now enrolled over 60% of patients for pivotal TMB-001 Phase 3 ASCEND clinical trial -

Exhibit 99.1 Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results - Timber has now enrolled over 60% of patients for pivotal TMB-001 Phase 3 ASCEND clinical trial - WARREN, NJ, May 15, 2023 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commerci

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 TIMBER PHARMACEUTICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

Subsidiaries of the Registrant.*

EX-21.1 3 tmbr-20221231xex21d1.htm EX-21.1 Exhibit 21.1 SUBSIDIARIES OF TIMBER PHARMACEUTICALS, INC. As of December 31, 2022, Timber Pharmaceuticals, Inc.’s subsidiaries are as follows: ● BioPharmX, Inc. (Nevada corporation) ● Timber Pharmaceuticals Australia Pty Ltd. (Australian proprietary limited company) ● Timber Pharmaceuticals LLC (Delaware LLC)

J UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 TIMBER PHARMACEU

J UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Comm

Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results - Lead asset TMB-001 is only compound to receive official orphan drug designation from European Commission for two severe subtypes of con

EX-99.1 2 tmbr-20230331xex99d1.htm EX-99.1 Exhibit 99.1 Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results - Lead asset TMB-001 is only compound to receive official orphan drug designation from European Commission for two severe subtypes of congenital ichthyosis, ARCI and XLRI - Timber has enrolled 50% of patients for pivotal TMB-001 Ph

Lease Agreement, dated February 8, 2023, by and between Timber Pharmaceuticals, Inc. and Paulus, Sokolowski and Sartor, LLC.*Ù

Exhibit 10.34 SUBLEASE AGREEMENT THIS SUBLEASE ("Sublease”) is made as of the 8th day of February 2023, by and between PAULUS, SOKOLOWSKI and SARTOR, LLC a New Jersey limited liability company ("Sublessor") and TIMBER PHARMACEUTICALS, Inc. a Delaware Corporation ("Sublessee"). BACKGROUND ASublessor leases certain premises (the "'Premises'") frorn.S/K WARREN ASSOCIATES. LLC, a New Jersey limited li

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-374

J UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2023 TIMBER PHARMAC

J UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2023 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Co

NYSE American: TMBR Safe Harbor Statement 2 Certain statements contained in this PowerPoint presentation describing Timber’s technology and development program, including, without limitation, statements containing the words “expects,” “anticipates,”

Exhibit 99.1 NYSE American: TMBR Corporate Overview February 2023 NYSE American: TMBR Safe Harbor Statement 2 Certain statements contained in this PowerPoint presentation describing Timber’s technology and development program, including, without limitation, statements containing the words “expects,” “anticipates,” “believes,” and words of similar import, constitute “forward - looking statements” w

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Com

Timber Pharmaceuticals to Host Investor Business Briefing: Milestone Achievements and Forward Outlook Virtual Business Briefing with Q&A to be webcast on December 20, 2022 at 10:30 am ET

Exhibit 99.1 Timber Pharmaceuticals to Host Investor Business Briefing: Milestone Achievements and Forward Outlook Virtual Business Briefing with Q&A to be webcast on December 20, 2022 at 10:30 am ET BASKING RIDGE, NJ, December 14, 2022 (NEWMEDIA WIRE) - - Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and comm

Timber Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards

Exhibit 99.1 Timber Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards BASKING RIDGE, NJ, December 9, 2022 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the Compan

J UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 TIMBER PHARMAC

J UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Co

Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results -Timber Received Orphan Designation from European Commission for Lead Asset TMB-001- -Recruitment for the pivotal Phase 3 ASCEND clinical trial continu

Exhibit 99.1 Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results -Timber Received Orphan Designation from European Commission for Lead Asset TMB-001- -Recruitment for the pivotal Phase 3 ASCEND clinical trial continues to progress; expected to enroll more than 140 patients with moderate to severe Congenital Ichthyosis- BASKING RIDGE, NJ, November 14,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 TIMBER PHARMACE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Com

Certificate of Amendment of Certificate of Incorporation, as amended, of Timber Pharmaceuticals, Inc., dated November 7, 2022, incorporated by reference to the Exhibit 3.1 to our Current Report on Form 8-K (File No. 001-37411), filed with the SEC on November 9, 2022).

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF TIMBER PHARMACEUTICALS, INC. Timber Pharmaceuticals, Inc., a corporation organized under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify: FIRST: The name of the corporation is Timber Pharmaceuticals, Inc. The Corporation’s original Certificate of Incorporation was filed with th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 TIMBER PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Comm

Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock Split

Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock Split BASKING RIDGE, NJ, November 8, 2022 – Timber Pharmaceuticals, Inc., (NYSE American: TMBR) ("Timber" or the "Company"), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, announced today that it will effect a 1-for-50 reverse stock spl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 TIMBER PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 TIMBER PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Comm

Timber Pharmaceuticals Announces Halt of Common Stock Trading Compliance with NYSE Listing Requirements Contingent on Stockholder Approval of Reverse Stock Split at Special Meeting of Stockholders on November 7, 2022 and Consummation of Reverse Stock

Exhibit 99.1 Timber Pharmaceuticals Announces Halt of Common Stock Trading Compliance with NYSE Listing Requirements Contingent on Stockholder Approval of Reverse Stock Split at Special Meeting of Stockholders on November 7, 2022 and Consummation of Reverse Stock Split BASKING RIDGE, NJ, November 3, 2022 — Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmac

Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital

Exhibit 99.1 Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive Ichthyosis - Regulatory milestones improve path to filing a European Marketing Authorization Application - - Company plans to submit additional application for orphan des

J UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2022 TIMBER PHARMAC

J UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2022 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Certificate of Designation of Preferences, Rights and Limitations of Series B Mirroring Preferred Stock filed with the Secretary of State of the State of Delaware on October 3, 2022

Exhibit 3.1 ? TIMBER PHARMACEUTICALS, INC. ? CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B MIRRORING PREFERRED STOCK ? PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW ? The undersigned, John Koconis, does hereby certify that: ? 1. He is the President of Timber Pharmaceuticals, Inc., a Delaware corporation (the ?Corporation?). ? 2. The Corporation is

Form of Series B Mirroring Preferred Stock Certificate

Exhibit 3.2 ? ? ? ? ? ? Incorporated Under ? P-[?] ? the Laws of the State of Delaware ? [?] ? ? ? ? TIMBER PHARMACEUTICALS, INC. Series B Mirroring Preferred Stock THIS CERTIFIES THAT [?] is the record holder of [?] [(?)] shares of Series B Mirroring Preferred Stock transferable only on the books of the Corporation by the holder hereof, in person or by duly authorized attorney, upon surrender of

Form of Securities Purchase Agreement, dated October 3, 2022, by and among Timber Pharmaceuticals, Inc. and the purchaser signatories thereto

? Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of October 3, 2022, between Timber Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and co

Form of Series 2 Warrant

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Timber Pharmaceuticals Announces $1.3 Million Registered Direct Offering

Exhibit 99.1 Timber Pharmaceuticals Announces $1.3 Million Registered Direct Offering ? BASKING RIDGE, NJ, October 3, 2022 (GLOBE NEWSWIRE) - via NewMediaWire -Timber Pharmaceuticals, Inc. (?Timber? or the ?Company?) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today annou

13,000,000 Shares of Common Stock Series 1 Warrants to Purchase 13,000,000 Shares of Common Stock 13,000,000 Shares of Common Stock underlying the Series 1 Warrants

Filed Pursuant to Rule 424(b)(5) Registration No. 333-255743 PROSPECTUS SUPPLEMENT (To Prospectus dated May 4, 2021) 13,000,000 Shares of Common Stock Series 1 Warrants to Purchase 13,000,000 Shares of Common Stock 13,000,000 Shares of Common Stock underlying the Series 1 Warrants We are offering 13,000,000 shares of Timber Pharmaceuticals, Inc. (the ?Company,? ?we,? ?our? or ?us?) Common Stock, p

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

J ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2022 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation)

Form of Series 1 Warrant

Exhibit 4.1 SERIES 1 COMMON STOCK PURCHASE WARRANT ? TIMBER PHARMACEUTICALS, INC. ? ? ? Warrant Shares: ? Issue Date: October 3, 2022 ? ? ? ? ? Initial Exercise Date: October 3, 2022 ? THIS SERIES 1 COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions

Regulation FD Disclosure

J ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2022 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporatio

NYSE American: TMBR Safe Harbor Statement 2 Certain statements contained in this PowerPoint presentation describing Timber’s technology and development program, including, without limitation, statements containing the words “expects,” “anticipates,”

Exhibit 99.1 Building Bridges in Medical Dermatology Investor Presentation September 2022 NYSE American: TMBR NYSE American: TMBR Safe Harbor Statement 2 Certain statements contained in this PowerPoint presentation describing Timber?s technology and development program, including, without limitation, statements containing the words ?expects,? ?anticipates,? ?believes,? and words of similar import,

Completion of Acquisition or Disposition of Assets

J ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2022 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events

J ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2022 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation)

Timber Pharmaceuticals Announces Notification of NYSE American Continued Listing Deficiency

Exhibit 99.1 Timber Pharmaceuticals Announces Notification of NYSE American Continued Listing Deficiency BASKING RIDGE, NJ, August 29, 2022 ? Timber Pharmaceuticals, Inc. ("Timber" or the ?Company?) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it had r

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.

TMBR / Timber Pharmaceuticals Inc / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Timber Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 887080109 (CUSIP Number) August 4, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th

Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2022 Financial Results Timber Enrolls First Patients in Phase 3 ASCEND Clinical Trial after Receiving Breakthrough Designation from FDA for Lead Asset TMB-001

Exhibit 99.1 Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2022 Financial Results Timber Enrolls First Patients in Phase 3 ASCEND Clinical Trial after Receiving Breakthrough Designation from FDA for Lead Asset TMB-001 ? BASKING RIDGE, NJ, August 11, 2022 - Timber Pharmaceuticals, Inc. ("Timber" or the ?Company?) (NYSE American: TMBR), a biopharmaceutical company focu

Financial Statements and Exhibits, Results of Operations and Financial Condition

J ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one)

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Form of Common Warrant

EX-4.2 3 tmbr-20220804xex4d2.htm EX-4.2 Exhibit 4.2 COMMON STOCK PURCHASE WARRANT TIMBER PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: August 8, 2022 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at an

Timber Pharmaceuticals Announces Closing of $8.0 Million Public Offering

Exhibit 99.3 Timber Pharmaceuticals Announces Closing of $8.0 Million Public Offering Basking Ridge, NJ, August 8, 2022 (GLOBE NEWSWIRE) - via NewMediaWire - Timber Pharmaceuticals, Inc. (?Timber? or the ?Company?) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the closing

Timber Pharmaceuticals Announces Pricing of $8.0 Million Public Offering

Exhibit 99.2 Timber Pharmaceuticals Announces Pricing of $8.0 Million Public Offering Basking Ridge, NJ, August 4, 2022 (GLOBE NEWSWIRE) - via NewMediaWire - Timber Pharmaceuticals, Inc. (?Timber? or the ?Company?) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the pricing

Form of Pre-Funded Warrant

Exhibit 4.1 ? PRE-FUNDED COMMON STOCK PURCHASE WARRANT ? Timber Pharmaceuticals, Inc. Warrant Shares: Initial Exercise Date: August 8, 2022 ? THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or

SECURITIES PURCHASE AGREEMENT

? Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of August 4, 2022, between Timber Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and con

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

J ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (

46,583,333 Shares of Common Stock Pre-Funded Warrants to Purchase up to 20,083,334 Shares of Common Stock Common Warrants to Purchase up to 66,666,667 Shares of Common Stock Shares of Common Stock underlying the Pre-Funded Warrants and Common Warrant

TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(4)? ?Registration No. 333-265974? PROSPECTUS 46,583,333 Shares of Common Stock Pre-Funded Warrants to Purchase up to 20,083,334 Shares of Common Stock Common Warrants to Purchase up to 66,666,667 Shares of Common Stock Shares of Common Stock underlying the Pre-Funded Warrants and Common Warrants We are offering 46,583,333 shares of common stock, tog

August 3, 2022

August 3, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

August 3, 2022

August 3, 2022 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Timber Pharmaceuticals, Inc. Registration Statement on Form S-1 (Registration No. 333-265974) - Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best efforts basis in an offeri

Form of Pre-Funded Warrant.*

EX-4.8 2 tm2220067d4ex4-8.htm EXHIBIT 4.8 EXHIBIT 4.8 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Timber Pharmaceuticals, Inc. Warrant Shares: Initial Exercise Date: , 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter

Form of Securities Purchase Agreement.*

Exhibit 10.31 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of , 2022, between Timber Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions s

Form of Common Warrant.*

EXHIBIT 4.9 COMMON STOCK PURCHASE WARRANT Timber Pharmaceuticals, Inc. Warrant Shares: Initial Exercise Date: , 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the ?Initial

Form of Pre-Funded TardiMed Warrant (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed with the SEC on August 1, 2022).

? Exhibit 4.1 ? NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG

As filed with the Securities and Exchange Commission on August 2, 2022

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 2, 2022 Registration No.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

J ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2022 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (C

Letter Agreement, dated July 27, 2022, between Timber Pharmaceuticals, Inc. and TardiMed Sciences LLC.

EX-10.1 3 tmbr-20220727xex10d1.htm EX-10.1 Exhibit 10.1 Timber Pharmaceuticals, Inc. 110 Allen Road, Suite 401 Basking Ridge, NJ 07920 July 27, 2022 TardiMed Sciences LLC Attn: Mr. Michael Derby 303 South Broadway, Suite 215 Tarrytown, NY 10591 Re:Letter Agreement Dear Mr. Derby: This letter agreement (this “Agreement”) is entered into in connection with the redemption rights under the Series A Pr

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2022 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (C

Amendment No. 1 to the Asset Acquisition Agreement, dated July 20, 2022, by and among Timber Pharmaceuticals, Inc., Patagonia Pharmaceuticals LLC, Jonathan Rome and Zachary Rome (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on July 26, 2022).#

Exhibit 10.1 AMENDMENT TO ASSET ACQUISITION AGREEMENT (THIS ?AMENDMENT?) Reference is made to that certain Asset Acquisition Agreement, dated February 28, 2019 (the ?Agreement?) by and among Timber Pharmaceuticals LLC, a Delaware limited liability company (the ?Company?), Patagonia Pharmaceuticals LLC, a New Jersey limited liability company (?Patagonia?), Jonathan Rome (?J Rome?) and Zachary Rome

Power of Attorney (included in the signature page to this registration statement).^

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 1, 2022 Registration No.

Filing Fee Table.^

Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Timber Pharmaceuticals, Inc.

Financial Statements and Exhibits, Other Events

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2022 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (C

Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital Ichthyosis - Pivotal trial expected to enroll more than 140 patients with moderate to severe congenital ichthyosis at leading r

Exhibit 99.1 ? Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital Ichthyosis - Pivotal trial expected to enroll more than 140 patients with moderate to severe congenital ichthyosis at leading research centers in the U.S., Canada, Italy, France, and Germany - BASKING RIDGE, NJ, June 23, 2022 ? Timber Pharmaceuticals, Inc. ("Tim

NYSE American: TMBR Safe Harbor Statement 2 Certain statements contained in this PowerPoint presentation describing Timber’s technology and development program, including, without limitation, statements containing the words “expects,” “anticipates,”

Exhibit 99.1 Building Bridges in Medical Dermatology Investor Presentation June 2022 NYSE American: TMBR NYSE American: TMBR Safe Harbor Statement 2 Certain statements contained in this PowerPoint presentation describing Timber?s technology and development program, including, without limitation, statements containing the words ?expects,? ?anticipates,? ?believes,? and words of similar import, cons

Regulation FD Disclosure, Financial Statements and Exhibits

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (C

Submission of Matters to a Vote of Security Holders

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Co

Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosis Company preparing to dose first patients in pivotal Phase 3 ASCEND clinical trial

Exhibit 99.1 ? ? Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosis Company preparing to dose first patients in pivotal Phase 3 ASCEND clinical trial BASKING RIDGE, NJ, May 31, 2022 ? Timber Pharmaceuticals, Inc. ("Timber" or the ?Company?) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the devel

Financial Statements and Exhibits, Other Events

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2022 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Co

Amended and Restated Bylaws of Timber Pharmaceuticals, Inc., as amended (incorporated by reference to Exhibit 3.1 to our Quarterly Report on Form 10-Q (File No. 001-37411) filed with the SEC on May 12, 2022).

Exhibit 3.1 ? AMENDED AND RESTATED BY-LAWS OF BIOPHARMX CORPORATION (a Delaware corporation) ARTICLE I STOCKHOLDERS Section 1.Certificates Representing Stock. (a) Certificates representing stock in BioPharmX Corporation (?the Corporation?) shall be signed by, or in the name of, the Corporation by the Chairman or Vice-Chairman of the Board of Directors, if any, or by the President or a Vice-Preside

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Co

Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2022 Financial Results Lead Asset TMB-001 Receives Fast Track Designation in Advance of Phase 3 Study Initiation by June 30, 2022

Exhibit 99.1 ? ? Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2022 Financial Results Lead Asset TMB-001 Receives Fast Track Designation in Advance of Phase 3 Study Initiation by June 30, 2022 ? BASKING RIDGE, NJ, May 12, 2022 - Timber Pharmaceuticals, Inc. ("Timber" or the ?Company?) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the dev

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one)

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Other Events

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (

Timber Pharmaceuticals Announces Fast Track Designation Granted by FDA for TMB-001 in Severe Subtypes of Congenital Ichthyosis - Company expects to launch pivotal Phase 3 ASCEND clinical trial to evaluate TMB-001 within the next 60 days -

Exhibit 99.1 ? ? Timber Pharmaceuticals Announces Fast Track Designation Granted by FDA for TMB-001 in Severe Subtypes of Congenital Ichthyosis - Company expects to launch pivotal Phase 3 ASCEND clinical trial to evaluate TMB-001 within the next 60 days - BASKING RIDGE, NJ, April 28, 2022 ? Timber Pharmaceuticals, Inc. ("Timber" or the ?Company?) (NYSE American: TMBR), a clinical-stage biopharmace

Other Events

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 ? ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive P

our definitive proxy statement on Schedule 14A filed with the SEC on April 22, 2022;

Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2022 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (

Amendment No. 1 to Amended and Restated Bylaws

? Exhibit 3.1 ? AMENDMENT NO. 1 TO THE AMENDED AND RESTATED BYLAWS OF TIMBER PHARMACEUTICALS, INC. ? This Amendment No. 1 to the Bylaws of Timber Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), as amended to date (the ?Bylaws?) is made as of this 10th day of April, 2022. 1. The Bylaws are hereby amended by replacing the paragraph titled ?Quorum? in existing Section 7 of Article I of

Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2021 Financial Results Company Plans to Initiate Phase 3 Study for TMB-001 in Q2 2022

Exhibit 99.1 ? Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2021 Financial Results Company Plans to Initiate Phase 3 Study for TMB-001 in Q2 2022 ? BASKING RIDGE, NJ, March 31, 2022 - Timber Pharmaceuticals, Inc. ("Timber" or the ?Company?) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to our Annual Report on Form 10-K (File No. 001-37411), filed with the SEC on March 31, 2022).

Exhibit 21.1 ? SUBSIDIARIES OF TIMBER PHARMACEUTICALS, INC. ? As of December 31, 2021, Timber Pharmaceuticals, Inc.?s subsidiaries are as follows: ? ? BioPharmX, Inc. (Nevada corporation) ? Timber Pharmaceuticals Australia Pty Ltd. (Australian proprietary limited company) ? Timber Pharmaceuticals LLC (Delaware LLC)

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2022 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commis

Timber Pharmaceuticals Announces Late-Breaking Presentation at the American Academy of Dermatology 2022 Annual Meeting - Sub-analysis of the Phase 2b CONTROL study in congenital ichthyosis demonstrates treatment success with TMB-001 regardless of sub

Exhibit 99.1 Timber Pharmaceuticals Announces Late-Breaking Presentation at the American Academy of Dermatology 2022 Annual Meeting - Sub-analysis of the Phase 2b CONTROL study in congenital ichthyosis demonstrates treatment success with TMB-001 regardless of subtype ? BASKING RIDGE, NJ, March 25, 2022 ? Timber Pharmaceuticals, Inc. (?Timber? or the ?Company?) (NYSE American: TMBR), a biopharmaceu

EXHIBIT 1

Altium Capital Management, LP SC 13G/A Page 9 of 9 EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.

TMBR / Timber Pharmaceuticals Inc / Altium Capital Management LP - AMENDMENT TO SC 13G Passive Investment

SC 13G/A 1 tmbr-sc13ga123121.htm AMENDMENT TO SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Timber Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 887080109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Sta

TMBR / Timber Pharmaceuticals Inc / Hudson Bay Capital Management LP - TMBR 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Timber Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 887080109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p

Financial Statements and Exhibits, Other Events

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2022 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation)

Timber Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA for TMB-001 in Moderate to Severe Congenital Ichthyosis - Full data from Phase 2b CONTROL study presented at 2022 Winter Clinical Dermatology Conference - - Company plans to in

Exhibit 99.1 Timber Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA for TMB-001 in Moderate to Severe Congenital Ichthyosis - Full data from Phase 2b CONTROL study presented at 2022 Winter Clinical Dermatology Conference - - Company plans to initiate Phase 3 study in second quarter of 2022 - BASKING RIDGE, NJ, February 3, 2022 ? Timber Pharmaceuticals, Inc. ("Timber" or the ?Com

As filed with the Securities and Exchange Commission on January 28, 2022

As filed with the Securities and Exchange Commission on January 28, 2022 Registration No.

TMBR / Timber Pharmaceuticals Inc / Empery Asset Management, LP - TIMBER PHARMACEUTICALS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Timber Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 887080109 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to w

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation)

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2021 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Comm

Building Bridges in Medical Dermatology Investor Presentation December 2021 NYSE American: TMBR

Exhibit 99.1 Building Bridges in Medical Dermatology Investor Presentation December 2021 NYSE American: TMBR NYSE American: TMBR Safe Harbor Statement 2 Certain statements contained in this PowerPoint presentation describing Timber?s technology and development program, including, without limitation, statements containing the words ?expects,? ?anticipates,? ?believes,? and words of similar import,

Building Bridges in Medical Dermatology TMB - 001 Phase 2b CONTROL Study Results Conference Call November 22, 2021 NYSE American: TMBR

Exhibit 99.1 Building Bridges in Medical Dermatology TMB - 001 Phase 2b CONTROL Study Results Conference Call November 22, 2021 NYSE American: TMBR ? NYSE American: TMBR Safe Harbor Statement 2 Certain statements contained in this PowerPoint presentation describing Timber?s technology and development program, including, without limitation, statements containing the words ?expects,? ?anticipates,?

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2021 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one)

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2021 Financial Results Positive Top Line Phase 2b Study Data for Lead Asset TMB-001 and Capital Raise of $17.25 Million Announced Subsequent to Quarter End

Exhibit 99.1 ? ? Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2021 Financial Results Positive Top Line Phase 2b Study Data for Lead Asset TMB-001 and Capital Raise of $17.25 Million Announced Subsequent to Quarter End ? BASKING RIDGE, NJ, November 15, 2021 - Timber Pharmaceuticals, Inc. ("Timber" or the ?Company?) (NYSE American: TMBR), a biopharmaceutical company fo

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation

Form of Warrant (incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K (File No. 001-37411), filed with the SEC on November 4, 2021.

Exhibit 4.2 EXHIBIT A-1 COMMON STOCK PURCHASE WARRANT Timber Pharmaceuticals, Inc. Warrant Shares: Issue Date: , 2021 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the ?Initia

Timber Pharmaceuticals, Inc. 21,325,000 Shares of Common Stock Pre-funded Warrants to Purchase up to 2,112,500 Shares of Common Stock Warrants to Purchase up to 23,437,500 Shares of Common Stock

424B5 1 tm2131946d1424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-255743 PROSPECTUS SUPPLEMENT (To Prospectus dated May 11, 2021) Timber Pharmaceuticals, Inc. 21,325,000 Shares of Common Stock Pre-funded Warrants to Purchase up to 2,112,500 Shares of Common Stock Warrants to Purchase up to 23,437,500 Shares of Common Stock We are offering up to 21,325,000 shares of our commo

Timber Pharmaceuticals Announces Proposed Public Offering

Exhibit 99.1 Timber Pharmaceuticals Announces Proposed Public Offering Basking Ridge, NJ, November 2, 2021 (GLOBE NEWSWIRE) - via NewMediaWire - Timber Pharmaceuticals, Inc. (?Timber? or the ?Company?) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it intends to offer

Underwriting Agreement, dated November 2, 2021 by and between Timber Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC.

Exhibit 1.1 21,325,000 SHARES of Common Stock 23,437,500 COMMON WARRANTS (EXERCISABLE FOR 23,437,500 WARRANT SHARES) AND 2,112,500 PRE-FUNDED WARRANTS (EXERCISABLE FOR 2,112,500 WARRANT SHARES) TIMBER PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT November 2, 2021 H.C. Wainwright & Co., LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o H.C. Wainwright & Co

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2021 TIMBER PHARMACEUTICALS, INC. (Exact Name of registrant as Specified in its Charter) Delaware 001-37411 59-3843182 (State or Other Jurisdiction of incorporation) (Comm

Form of Pre-funded Warrant.

Exhibit 4.1 EXHIBIT A-2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Timber Pharmaceuticals, Inc. Warrant Shares: Issue Date: , 2021 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the da

Timber Pharmaceuticals Announces Pricing of $15 Million Public Offering

Exhibit 99.2 Timber Pharmaceuticals Announces Pricing of $15 Million Public Offering Basking Ridge, NJ, November 3, 2021 (GLOBE NEWSWIRE) - via NewMediaWire - Timber Pharmaceuticals, Inc. (?Timber? or the ?Company?) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the pricing

Subject to completion, dated November 2, 2021

Filed Pursuant to Rule 424(b)(5) Registration No. 333-255743 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not a

Financial Statements and Exhibits, Other Events

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2021 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation)

Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis - Data demonstrate reduction in targeted and overall severity of CI in patients treated with topical I

Exhibit 99.1 ? Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis - Data demonstrate reduction in targeted and overall severity of CI in patients treated with topical IPEG? TMB-001 (topical isotretinoin) - Company planning for end-of-Phase 2 meeting with FDA in the beginning of 2022 - Phase 3 study is

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2021 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation)

September 27, 2021

Exhibit 99.1 ? ? 110 Allen Road Suite 401 Basking Ridge, NJ 07920 ? ? ? September 27, 2021 ? ? Joseph Lucchese ? ? Subject: Employment Offer ? ? Dear Joseph, ? On behalf of Timber Pharmaceuticals Inc (?Timber? or the ?Company?), I am pleased to extend to you an offer to continue your role as Executive Vice President, Finance and Chief Financial Officer, but on a full time basis. This position will

Amendment to the Timber Pharmaceuticals, Inc. 2020 Omnibus Equity Incentive Plan, dated April 20, 2021 (incorporated by reference to Exhibit 4.9 to our Registration on Form S-8 (File No. 333-259830) filed with the SEC on September 27, 2021).#

EX-4.9 2 tmb-20210927xex4d9.htm EX-4.9 Exhibit 4.9 AMENDMENT TO TIMBER PHARMACEUTICALS, INC. 2020 OMNIBUS EQUITY INCENTIVE PLAN Dated: April 20, 2021 This Amendment amends the Timber Pharmaceuticals, Inc. 2020 Omnibus Equity Incentive Plan (the “Plan”). All capitalized terms not defined herein shall have the meanings set forth in the Plan. R E C I T A L S WHEREAS, Section 17.2 of the Plan reserves

As filed with the Securities and Exchange Commission on September 27, 2021

As filed with the Securities and Exchange Commission on September 27, 2021 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2021 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2021 TIMBER PHARMAC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2021 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Co

Building Bridges in Medical Dermatology Investor Presentation September 2021 NYSE American: TMBR

Exhibit 99.1 Building Bridges in Medical Dermatology Investor Presentation September 2021 NYSE American: TMBR NYSE American: TMBR Safe Harbor Statement 2 Certain statements contained in this PowerPoint presentation describing Timber?s technology and development program, including, without limitation, statements containing the words ?expects,? ?anticipates,? ?believes,? and words of similar import,

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT This Agreement will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on the date hereof with respect to the beneficial ownership by the undersigned of the shares of Common Stock of Timber Pharmaceuticals, Inc.

TMBR / Timber Pharmaceuticals Inc / TardiMed Sciences LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6) Timber Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 887080109 (CUSIP Number) Michael Derby TardiMed Sciences LLC 303 South Broadway, Suite 125 Tarrytown, NY 10591 Telephone: (201) 645-476

TMBR / Timber Pharmaceuticals Inc / TardiMed Sciences LLC - SCHEDULE 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5) Timber Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 887080109 (CUSIP Number) Michael Derby TardiMed Sciences LLC 303 South Broadway, Suite 125 Tarrytown, NY 10591 Telephone: (201) 645-476

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT This Agreement will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on the date hereof with respect to the beneficial ownership by the undersigned of the shares of Common Stock of Timber Pharmaceuticals, Inc.

TMBR / Timber Pharmaceuticals Inc / TardiMed Sciences LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4) Timber Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 887080109 (CUSIP Number) Michael Derby TardiMed Sciences LLC 303 South Broadway, Suite 125 Tarrytown, NY 10591 Telephone: (201) 645-476

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT This Agreement will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on the date hereof with respect to the beneficial ownership by the undersigned of the shares of Common Stock of Timber Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2021 TIMBER PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2021 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commi

Timber Pharmaceuticals Announces Last Patient Last Visit in Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis - Topline results expected to be announced in the fourth quarter of 2021 - - Company preparing for an En

Exhibit 99.1 ? Timber Pharmaceuticals Announces Last Patient Last Visit in Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis ? - Topline results expected to be announced in the fourth quarter of 2021 - - Company preparing for an End-of-Phase 2 meeting with the FDA - Basking Ridge, N.J., August 24, 2021 ? Timber Pharmaceuticals, Inc. ("Timber" or the ?Company?) (

Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2021 Financial Results

Exhibit 99.1 ? Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2021 Financial Results BASKING RIDGE, NJ, August 10, 2021 - Timber Pharmaceuticals, Inc. ("Timber" or the ?Company?) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one)

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 ? TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-37411 59-3843182 (State or other jurisdiction of incorpora

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2021 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commissi

Building Bridges in Medical Dermatology Investor Presentation July 2021 NYSE American: TMBR

Exhibit 99.1 Building Bridges in Medical Dermatology Investor Presentation July 2021 NYSE American: TMBR NYSE American: TMBR Safe Harbor Statement 2 Certain statements contained in this PowerPoint presentation describing Timber?s technology and development program, including, without limitation, statements containing the words ?expects,? ?anticipates,? ?believes,? and words of similar import, cons

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2021 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Information required in proxy statement schedule 14A information PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

DEFA14A 1 tm2120552d1defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Information required in proxy statement schedule 14A information PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement

TMBR / Timber Pharmaceuticals Inc / TardiMed Sciences LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3) Timber Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 887080109 (CUSIP Number) Michael Derby TardiMed Sciences LLC 303 South Broadway, Suite 125 Tarrytown, NY 10591 Telephone: (201) 645-476

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT This Agreement will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on the date hereof with respect to the beneficial ownership by the undersigned of the shares of Common Stock of Timber Pharmaceuticals, Inc.

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Information required in proxy statement schedule 14A information PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Information required in proxy statement schedule 14A information PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission

TIMBER PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING

EX-99.1 2 tm2118480d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 TIMBER PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING Basking Ridge, NJ, June 3, 2021 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that on June 3,

Timber Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2b CONTROL Study Evaluating TMB-001 in Congenital Ichthyosis - Company plans to ask for end-of-Phase 2 meeting with FDA by end of 2021 -

Exhibit 99.1 Timber Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2b CONTROL Study Evaluating TMB-001 in Congenital Ichthyosis - Company plans to ask for end-of-Phase 2 meeting with FDA by end of 2021 - Basking Ridge, N.J., May 26, 2021 ? Timber Pharmaceuticals, Inc. ("Timber" or the ?Company?) (NYSE American: TMBR), a biopharmaceutical company focused on the development and

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2021 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commissi

TIMBER PHARMACEUTICALS, INC. 7,823,410 Shares of Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-255742 PROSPECTUS TIMBER PHARMACEUTICALS, INC. 7,823,410 Shares of Common Stock This prospectus of Timber Pharmaceuticals, Inc., a Delaware corporation (the ?Company? or ?Timber?), relates solely to the resale by the investors listed in the section of this prospectus entitled ?Selling Stockholders? (the ?Selling Stockholders?) of up to 7,823,41

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the annual period ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001

Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2021 Financial Results

Exhibit 99.1 Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2021 Financial Results BASKING RIDGE, NJ, May 11, 2021 - Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and ann

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37411 TIMBER PHA

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commissi

Timber Pharmaceuticals, Inc. 110 Allen Road, Suite 401 Basking Ridge, NJ 07920

Timber Pharmaceuticals, Inc. 110 Allen Road, Suite 401 Basking Ridge, NJ 07920 May 7, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Timber Pharmaceuticals, Inc. (the ?Company?) Registration Statement on Form S-3 (File No. 333-255743) Ladies and Gentlemen: In accordance with Rule 461 under the Securities

Timber Pharmaceuticals, Inc. 110 Allen Road, Suite 401 Basking Ridge, NJ 07920

Timber Pharmaceuticals, Inc. 110 Allen Road, Suite 401 Basking Ridge, NJ 07920 May 7, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Timber Pharmaceuticals, Inc. (the ?Company?) Registration Statement on Form S-3 (File No. 333-255742) Ladies and Gentlemen: In accordance with Rule 461 under the Securities

- FORM S-3

As filed with the Securities and Exchange Commission on May 3, 2021 Registration No.

- FORM S-3

As filed with the Securities and Exchange Commission on May 3, 2021 Registration No.

Proxy Supplement on Schedule 14A, filed with the SEC on April 29, 2021

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Information required in proxy statement schedule 14A information PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2021 TIMBER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37411 59-3843182 (State or other jurisdiction of incorporation) (Commis